Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RFUSIN2-AML1
- Development stage
- Phase 1
- Lead developer
- King's College London
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Subcutaneous, Intradermal
01
Overview
RFUSIN2-AML1 is an autologous or allogeneic cell-based vaccine consisting of acute myeloid leukemia (AML) cells that have been genetically modified using a lentiviral vector to express the costimulatory molecule B7.1 (CD80) and the cytokine interleukin-2 (IL-2). Developed by researchers at King's College London, this immunotherapy is designed to enhance the graft-versus-leukemia (GvL) effect or stimulate an endogenous anti-tumor immune response in patients with poor-prognosis AML or high-risk myelodysplastic syndrome (MDS). By expressing CD80 and secreting IL-2, the modified leukemic cells act as potent antigen-presenting cells, facilitating the activation and expansion of tumor-specific T cells.
- Other names
- AML Cell VaccineB7.1/IL-2 Immune Gene TherapyLentivirus Transduced AML Cells expressing B7.1 and IL-2
02
Targets
IL2RB (IL-2 receptor beta chain)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on RFUSIN2-AML1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RFUSIN2-AML1.